uniQure N.V., a leading pharmaceutical specialized in human gene therapy, has presented additional data from its clinical trial in hemophilia B patients at the 21st Congress of the European Hematology Association (EHA),  June 9-12, in Copenhagen. The Phase 1/2 clinical trial of AMT-060 titled “Trial of…

A recent clinical trial indicates that replacement therapy with plasma-derived factor VIII is associated with lower incidence for development of inhibitors in patients with severe hemophilia A. The study,“A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A,” was published in The New England Journal of…

  The difference in disease severity between Hemophilia A and B (HA, HB) was recently assessed in the study, “Clinical, Instrumental, Serological And Histological Findings Suggest That Hemophilia B May Be Less Severe Than Hemophilia A,” and published in Haematologica. HA and HB are caused by deficient clotting proteins,…

Facial and scalp swelling can be indicators of childhood hemophilia, but for children who are misdiagnosed and treated incorrectly, the effects of the disease’s elevated bleeding predisposition can be catastrophic. In the study, “Facial and Scalp Swelling in the Pediatric Population With Hemophilia: A Diagnosis Pitfall,” published in…

The safety and efficacy of emicizumab in patients with severe hemophilia A (HA) were recently evaluated in a study, “Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A,” published in The New England Journal Of Medicine. Hemophilia A is caused by a lack of blood clotting factor…

Chugai Pharmaceutical recently published data of a Phase I clinical study on the antibody emicizumab. The study, “Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A,” was published in The New England Journal of Medicine. The study revealed possible benefits from emicizumab  for the prevention of bleeding in…

Sports and physical activity can benefit people living with hemophilia, according to a recent study. Researchers in Germany and the United Kingdom investigated to find whether participating in sports can benefit adults with varying degrees of hemophilia severity. The report, “The impact of sport on health status,…

Catalyst Biosciences, developers of protease therapeutics for serious hemostasis and anti-complement conditions, and CMC ICOS Biologics, Inc., which manufactures therapeutic proteins, have partnered for the manufacture of a next generation hemophelia drug. Catalyst is developing CB 813d, a longer-acting Factor VIIa drug for hemophilia A and B inhibitor patients. “We selected CMC Biologics…

The National Hemophilia Foundation (NHF) and Impact Education, LLC (IMPACT) have jointly announced the fourth annual National Hemophilia Foundation Annual Meeting pre-conference symposium has been specifically designed for pharmacists — including specialty, home health, health plan, and managed Medicaid pharmacists — as well as for medical directors and other…

CSL Behring, a global biotherapeutics company focused on the development and delivery of innovative therapies that are used to treat coagulation disorders, announced this week that the European Commission has approved Idelvion (albutrepenonacog alfa), its long-acting albumin fusion protein for the treatment of bleeding in patients with hemophilia B…